Myeloid growth factors (MGFs) are used for the prophylaxis of febrile neutropenia and maintenance of scheduled dose delivery in the treatment of patients undergoing cancer chemotherapy. To spare cost and for patient convenience, in adults MGFs are used at schedules, doses, and durations that differ from the approved prescribing information of the U.S. Food and Drug Administration. These variations include rounding doses to convenient sizes, fewer days of treatment, a shorter interval between cycles, and same-day administration with chemotherapy. Some of these variations are supported by clinical trial results and practice guidelines.
.0021 Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules Althaus Betsy L. PharmD, BCOP 02 2007 5 5 2 2 229 229 234 234 0050229 10.6004/jnccn.2007.0022 Antibacterial
Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre and James Rosberg
with chemotherapy . Cancer 2003 ; 98 : 1072 – 1079 . 15 Glaspy J Bukowski R Steinberg D . Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology